WebTable 3: Dose modification in renal and hepatic impairment Drug Renal Impairment Hepatic Impairment Pertuzumab No dose reduction required for mild or moderate renal impairment. No dose recommendations for severe impairment due to limited data. No specific dose recommendations. Has not been studied in patients with hepatic impairment. WebThere is no data available on the use of docetaxel in severe renal impairment. No modifications required. Hepatic impairment Bilirubin (x ULN) AST/ALT (x ULN) Oxaliplatin dose Fluorouracil dose ≤ 1.5 and ≤ 1.5 100% 100% 1.5 - 3 and ≤ 3 100% Consider dose reduction* 3 – 5 or 3 – 5 50% Consider dose reduction* ...

NCCP Chemotherapy Regimen Pertuzumab and Trastuzumab …

WebDocetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel in combination with … WebIn patients with baseline moderate hepatic impairment receiving a reduced ZYTIGA ® dose of 250 mg, measure ALT, AST, and bilirubin prior to the start of treatment, every week for the first month, every two weeks for the following two months of treatment, and monthly thereafter. Promptly measure serum total bilirubin, AST, and ALT if clinical ... dsm criteria reactive attachment disorder

DailyMed - DOCETAXEL injection, solution

WebNational Center for Biotechnology Information WebModerate hepatic impairment; reduce initial dose by 1/3. Severe hepatic impairment, reduce initial dose by 1/2. Increase dose if no toxicity Table 3: Dose modification of DOCEtaxel in hepatic impairment Alkaline Phosphatase AST and/or ALT Serum Bilirubin Dose > 2.5 ULN and > 1.5 ULN 6 ULN and/or > 3.5 ULN (AST and ALT) WebDocetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions. Docetaxel binds to free … commercial property fredericksburg va